Rigel Pharmaceuticals price target raised to $49 from $40 at Citi

Citi raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $49 from $40 and keeps a Buy rating on the shares post the Q3 report. The firm says that while Gavreto posted an unexpectedly strong quarter with $7.1M in sales, Rigel’s pipeline stole the show with a strong early profile for R289 in lower-risk myelodysplastic syndromes.